Dicerna Pharmaceuticals (NASDAQ:DRNA) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.15), Fidelity Earnings reports. The firm had revenue of $8.04 million for the quarter, compared to the consensus estimate of $11.70 million. Dicerna Pharmaceuticals had a negative return on equity of 50.30% and a negative net margin of 737.93%.
NASDAQ:DRNA traded up $0.09 during trading hours on Friday, hitting $17.69. 824,800 shares of the company were exchanged, compared to its average volume of 465,156. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.65 and a quick ratio of 3.65. The company’s 50 day moving average price is $15.51 and its 200-day moving average price is $14.24. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -14.74 and a beta of 2.29. Dicerna Pharmaceuticals has a 52-week low of $9.31 and a 52-week high of $18.39.
In other Dicerna Pharmaceuticals news, COO James B. Weissman sold 15,000 shares of the company’s stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $18.00, for a total transaction of $270,000.00. Following the completion of the transaction, the chief operating officer now directly owns 29,704 shares in the company, valued at $534,672. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James B. Weissman sold 14,680 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $13.07, for a total transaction of $191,867.60. Following the completion of the sale, the insider now owns 9,800 shares of the company’s stock, valued at $128,086. The disclosure for this sale can be found here. Insiders have sold 42,180 shares of company stock valued at $686,868 over the last 90 days. 21.28% of the stock is currently owned by company insiders.
Several research analysts recently commented on DRNA shares. Robert W. Baird initiated coverage on shares of Dicerna Pharmaceuticals in a research note on Tuesday, October 29th. They set an “outperform” rating and a $27.00 price objective for the company. Leerink Swann boosted their target price on shares of Dicerna Pharmaceuticals from $22.00 to $26.00 in a research report on Friday, November 1st. BidaskClub raised shares of Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 5th. Finally, Chardan Capital reissued a “buy” rating and set a $18.00 target price on shares of Dicerna Pharmaceuticals in a research report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Dicerna Pharmaceuticals has an average rating of “Buy” and an average price target of $22.50.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Featured Article: Google Finance Portfolio Workaround
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.